{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-003253","form_type":"8-K","ticker":"SMNR","cik":"0001913577","company_name":"Semnur Pharmaceuticals, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.386339+00:00","generated_at":"2026-06-10T01:50:02.261458+00:00","sec_items":["1.01","2.03","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Denali Capital extension approved, ~$40.5M redeemed, up to $450k promissory note","bullets":["Shareholders approved extension to July 11, 2024 with monthly $50k deposits; $50k deposited for first month.","Approx 3.7M public shares redeemed for $40.5M ($10.92/share); public float reduced to ~4.54M shares.","Issued convertible promissory note up to $450k to FutureTech Capital (initial $50k), convertible at $10/share upon business combination.","Also approved founder share early conversion and removal of $5M net tangible asset redemption limitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-003253","json":"https://secwatch.observer/filing/0001013762-23-003253.json","markdown":"https://secwatch.observer/filing/0001013762-23-003253.md","text":"https://secwatch.observer/filing/0001013762-23-003253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/ea186607-8k425_denalicap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:50:02.261458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"339cc80c249f7d8f7240807d4ba050f734f61f7e","claim":"Semnur Pharmaceuticals, Inc. incurred convertible notes of up to $450,000 with FutureTech Capital LLC maturing upon the earlier of (i) the closing of the Company’s initial business combination and (ii) the date of the liquidation of the Company.","evidence_excerpt":"issued a convertible promissory note (the “Convertible Promissory Note”) in the total principal amount of up to $450,000 to FutureTech Capital LLC","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"up to $450,000"},{"label":"Counterparty","value":"FutureTech Capital LLC"},{"label":"Maturity","value":"upon the earlier of (i) the closing of the Company’s initial business combination and (ii) the date of the liquidation of the Company"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"41ef97e73af70b7a4b2f925265559beb68df3369","claim":"Semnur Pharmaceuticals, Inc.: Amended the amended and restated memorandum and articles of association to extend the date to consummate an initial business combination from October 11, 2023 to July 11, 2024, with monthly extension options (effective 2023-10-11).","evidence_excerpt":"Effective upon the approval of the Article Amendment Proposals, on October 11, 2023, the amended and restated memorandum and articles of association of the Company were amended pursuant to the resolutions set forth as Annex A, Annex B and Annex C to the definitive proxy statement relating to the Shareholder Meeting filed by the Company with the Securities and Exchange Commission on September 25, 2023, as amended on September 28, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-11"}],"fact_type":"governance_change"},{"claim_id":"55c6d42b866f30593dfdb18f8278637a15e1371f","claim":"Semnur Pharmaceuticals, Inc. entered into Convertible Promissory Note with FutureTech Capital LLC valued at total principal amount of up to $450,000 (effective 2023-10-11).","evidence_excerpt":"On October 11, 2023, Denali Capital Acquisition Corp. (the “Company”) issued a convertible promissory note (the “Convertible Promissory Note”) in the total principal amount of up to $450,000 to FutureTech Capital LLC, a Delaware limited liability company (“FutureTech”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"FutureTech Capital LLC"},{"label":"Value","value":"total principal amount of up to $450,000"},{"label":"Effective","value":"2023-10-11"}],"fact_type":"material_agreement"},{"claim_id":"423238d0046d1d7c9bb3a257b25df9cc09c4a13c","claim":"Semnur Pharmaceuticals, Inc. shareholders approved Extension Amendment Proposal to extend the date to consummate an initial business combination from October 11, 2023 to July 11, 2024 at the 2023-10-11 meeting.","evidence_excerpt":"Extension Amendment Proposal For Against Abstain Broker Non-Votes 8,934,390 573,143 0 0 Accordingly, the Extension Amendment Proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-11"}],"fact_type":"shareholder_vote"},{"claim_id":"805ceb3200a0bebab54b7d6538721c17e734debc","claim":"Semnur Pharmaceuticals, Inc. shareholders approved Founder Share Amendment Proposal to permit conversion of Class B ordinary shares into Class A ordinary shares on a one-for-one basis prior to initial business combination at the 2023-10-11 meeting.","evidence_excerpt":"Founder Share Amendment Proposal For Against Abstain Broker Non-Votes 8,934,389 573,144 0 0 Accordingly, the Founder Share Amendment Proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-11"}],"fact_type":"shareholder_vote"},{"claim_id":"9467a3644be0b4069d85674c87641704a3c8bf4c","claim":"Semnur Pharmaceuticals, Inc. shareholders approved Redemption Limitation Amendment Proposal to eliminate the limitation that the Company may not redeem Public Shares in an amount that would cause net tangible assets to be less than $5,000,001 at the 2023-10-11 meeting.","evidence_excerpt":"Redemption Limitation Amendment Proposal For Against Abstain Broker Non-Votes 8,934,390 573,143 0 0 Accordingly, the Redemption Limitation Amendment Proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000101376223003253/0001013762-23-003253-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}